

MYCOVACC

The CCS National Active Surveillance Study of Myocarditis and/or Pericarditis following mRNA COVID-19 Vaccination (MYCOVACC) is a multi-centre, pan-Canadian study funded by the Public Health Agency of Canada.

\$1.4M awarded to MYCOVACC to continue national study of COVID-19 and mRNA vaccines

New funding from the Public Health Agency of Canada will enable top Canadian cardiology researchers and clinicians to continue this multi-year study on the impact of COVID-19 and mRNA vaccines. MYCOVACC will receive an additional \$1.4 million in funding for its third year, bringing the total investment to \$5 million. Read the news release.


Read: Myocarditis and Pericarditis following mRNA COVID-19 Vaccination: 2024 Status and Management Update

McDonald, M.A., Kafil, T.S, Khoury, M., Luk, A.C., Wright, M.K, & Hawkins, N. M. (2024). Myocarditis and pericarditis following mRNA COVID-19 vaccination: 2024 Status and Management Update. Canadian Journal of Cardiology. https://doi.org/10.1016/j.cjca.2024.03.016


This brief review summarizes new evidence about the epidemiology and outcomes of patients with mRNA COVID-19 post-vaccine myocarditis and pericarditis. It also provides consensus guidance for evaluation, management, and follow-up. Finally, persistent knowledge gaps are identified that inform the MYCOVACC study and areas for future research.

New Patient and Healthcare Provider Resources

The CCS updated its post-vaccine myocarditis and pericarditis resources in collaboration with the Centre for Evidence-Based Implementation at McMaster University. The **2024 Status and Management Update** in the Canadian Journal of Cardiology is the basis for these resources, which are available in English and French.



Management Algorithm for Health Care Providers



Information for Patients

Watch: Myocarditis and Pericarditis after mRNA COVID-19 Vaccination: Status and Management Update (2024)



This CCS continuing professional development webinar provides an update on post-vaccine myocarditis and pericarditis from public health, cardiology, and family medicine perspectives. Dr. Anil Gupta chairs the session. The panelists are Dr. Tonja Stothart, Dr. Dalsy De la Cruz Davalos, Dr. Nat Hawkins, Dr. Tahir Kafil, and Dr. Alexander Singer.

Visit: Updated MYCOVACC Webpage

New resources described in this newsletter are available on the updated MYCOVACC webpage. Visit the updated webpage here.

Site Recruitment Update

MYCOVACC has recruited more than 30 study sites across Canada with the assistance of key research partner networks.

The CCS continues to actively recruit cardiac care centres, cardiology clinics and cardiologists from across Canada to contribute to the study. **Learn more**.

Related Research

Shenton, P., Schrader, S., Smith, J., Alafaci, A., Cox, N., Taylor, A., Hare, J., Jones, B., Crawford, N. W., Buttery, J. P., Cheng, D. R., & SAEFVIC VicSIS investigators (2024). Long term follow up and outcomes of Covid-19 vaccine associated myocarditis in Victoria, Australia: A clinical surveillance study. Vaccine, 42(3), 522-528. https://doi.org/10.1016/j.vaccine.2023.12.070

Email: mycovacc@ccs.ca

Website: https://ccs.ca/mycovacc/

Financial contribution from



Public Health

Agence de la santé Agency of Canada publique du Canada



Please click here to opt out of this mailing or to change your CCS communication preferences.

Canadian Cardiovascular Society | 1000-150 Elgin Street | Ottawa, ON K2P 1L4 CA

<u>Unsubscribe</u> | <u>Constant Contact Data Notice</u>